4X Blend GHRP-2/Tesamorelin/MGF/Ipamorelin

This four-peptide blend combines complementary growth hormone secretagogue (GHS) pathways to produce a synergistic effect on GH release. GHRP-2 acts as a potent ghrelin receptor (GHS-R1a) agonist that directly stimulates somatotroph cells in the anterior pituitary, while also suppressing somatostatin signaling. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that binds the GHRH receptor to stimulate pulsatile GH secretion through the cAMP/PKA signaling cascade. Ipamorelin is a selective GHS-R1a agonist notable for its specificity — it stimulates GH release without significantly affecting cortisol or prolactin levels, unlike less selective secretagogues. Mechano Growth Factor (MGF), a splice variant of IGF-1 (IGF-1Ec), acts downstream by activating satellite cells and promoting local tissue repair independent of circulating GH. The rationale for combining these four peptides lies in the well-documented synergy between GHRH-pathway agonists (tesamorelin) and ghrelin-pathway agonists (GHRP-2, ipamorelin). Research by Bowers et al. demonstrated that combined GHRH and GHRP administration produces GH release far exceeding the sum of individual responses. The addition of MGF introduces a local tissue-level growth factor that operates through a distinct mechanism, broadening the biological scope of the blend.

This four-peptide blend combines complementary growth hormone secretagogue (GHS) pathways to produce a synergistic effect on GH release. GHRP-2 acts as a potent ghrelin receptor (GHS-R1a) agonist that directly stimulates somatotroph cells in the anterior pituitary, while also suppressing somatostatin signaling. Tesamorelin is a synthetic analogue of growth hormone-releasing hormone (GHRH) that binds the GHRH receptor to stimulate pulsatile GH secretion through the cAMP/PKA signaling cascade. Ipamorelin is a selective GHS-R1a agonist notable for its specificity — it stimulates GH release without significantly affecting cortisol or prolactin levels, unlike less selective secretagogues. Mechano Growth Factor (MGF), a splice variant of IGF-1 (IGF-1Ec), acts downstream by activating satellite cells and promoting local tissue repair independent of circulating GH. The rationale for combining these four peptides lies in the well-documented synergy between GHRH-pathway agonists (tesamorelin) and ghrelin-pathway agonists (GHRP-2, ipamorelin). Research by Bowers et al. demonstrated that combined GHRH and GHRP administration produces GH release far exceeding the sum of individual responses. The addition of MGF introduces a local tissue-level growth factor that operates through a distinct mechanism, broadening the biological scope of the blend.

Research protocols typically study each component individually. GHRP-2 is commonly studied at 1-2 mcg/kg; tesamorelin at 1-2 mg; ipamorelin at 1 mcg/kg; MGF at 50-200 mcg. Blend ratios vary by protocol.

Store lyophilized (freeze-dried) powder at -20°C to 4°C in a dry environment protected from light. Unreconstituted peptide is stable for extended periods when stored properly.

Once reconstituted with bacteriostatic water or an appropriate solvent, store at 2-8°C and use within the timeframe specified on the Certificate of Analysis. Avoid repeated freeze-thaw cycles.

A Certificate of Analysis documenting purity, identity, and recommended storage conditions is included with every order.